2009-10-19: Biotechnology Report
3 leading Analysts; 2 Money Managers; and top management from 12 Sector Firms
examine this vital industry in this 70 page report from The Wall Street Transcript.
Order this Report
Development in Biotech Matthew Kaplan - Ladenburg Thalmann
Outlook for Large-Cap Biotechnology Maged Shenouda - UBS Investment Research
Post-Crunch Trends in Biotechnology Liana Moussatos - Wedbush Morgan Securities, Inc.
A Global Value Investment Strategy David Kliff - Diabetic Investor
Outlook for Global Healthcare Companies Serge Depatie - Natcan Investment Management Inc.
CEO Interviews (average 2,500 words): top management from 12 Sector Firms examine the outlook for its company and its sector. Firms interviewed include: ADVENTRX Pharmaceuticals, Inc., Advaxis, BioDelivery Sciences International, Inc, Cerus Corporation, CombiMatrix Corporation, DARA BioSciences, Inc., GenVec, Inc., Intellect Neurosciences, Inc, International Stem Cell Corporation, Novelos Therapeutics, Inc., Viropro, Inc., and ZIOPHARM Oncology, Inc.
Topics covered: Heightened M&A Activity - Trend Toward Orphan Disease Drug Development - Generic Drug Competition - Current Length Of FDA Approval Process - Ownership Ego Preventing Shareholder Returns - IPO And Secondary Offering Window Opening - Big Pharma R&D Pipeline - Decreased Clinical Development Risk - Impact Of Health Care Reform - Convergence Of Large-Cap Biotech And Pharmaceutical Companies - Easier Credit For Small Cap Biotech Companies - Developments In Cancer Chemotherapeutics - Gene Delivery Technology
ORDER THIS REPORT NOW! CLICK HERE
Companies covered: ADVENTRX (ANX); Abbott Labs (ABT); Advaxis (ADVX); Amedisys (AMED); Amgen (AMGN); Amylin Pharmaceuticals (AMLN); Antares Pharma (AIS); BioDelivery Sciences (BDSI); Biogen Idec (BIIB); Biomarin (BMRN); Boston Scientific (BSX); Bristol Myers (BMY); CVS Caremark (CVS); Celgene (CELG); Cerner (CRN); Cerus (CERS); Coke (KO); CombiMatrix (CBMX); Coventry Health Care (CVH); DARA (DARA); Eisai (ESALY); Eli Lilly (LLY); GenVec (GNVC); Gilead (GILD); GlaxoSmithKline (GSK); Health Management Associates (HMA); Human Genome Sciences (HGSI); Inspire Pharmaceuticals (ISPH); Intellect Neurosciences (ILNS.OB); InterMune (ITMN); International Stem Cell (ISCO.OB); Javelin Pharmaceuticals (JAV); Johnson & Johnson (JNJ); Keryx Biopharmaceuticals (KERX); Kraft (KFT); MAP Pharmaceuticals (MAPP); Medco (MHS); Merck (MRK); Merit Medical (MMSI); Novartis (NVS); Novelos (NVLT.OB); Novo Nordisk (NVO); Nutrisystem (NTRI); OSI Pharmaceutical (OSIP); Orexigen (OREX); Pepsi (PEP); Pfizer (PFE); Rite Aid (RAD); Schering-Plough (SGP); Takeda (TKPHF); Teva Pharmaceuticals (TEVA); Viropro (VPRO.PK); Walgreens (WAG); Wyeth (WYE); XOMA (XOMA); ZIOPHARM (ZIOP).
